C.R. Bard, Inc. v. M3 Systems, Inc.

120 F. Supp. 2d 1145, 2000 WL 875736
CourtDistrict Court, N.D. Illinois
DecidedJune 27, 2000
Docket93 C 4788
StatusPublished
Cited by4 cases

This text of 120 F. Supp. 2d 1145 (C.R. Bard, Inc. v. M3 Systems, Inc.) is published on Counsel Stack Legal Research, covering District Court, N.D. Illinois primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
C.R. Bard, Inc. v. M3 Systems, Inc., 120 F. Supp. 2d 1145, 2000 WL 875736 (N.D. Ill. 2000).

Opinion

MEMORANDUM OPINION AND ORDER

BUCKLO, District Judge.

C.R. Bard, Inc. (“Bard”) brought a patent infringement action against its competitor M3 Systems, Inc. (“M3”), which in turn raised antitrust counterclaims against Bard. A jury found in favor of M3 on the claims and counterclaims, and Bard appealed. The verdict on one of Bard’s three counterclaims was upheld, but the Federal Circuit vacated and remanded the damage award for redetermination. M3 seeks an entry of judgment and post-judgment interest, while Bard claims a new trial is necessary to fairly determine damages on the surviving counterclaim. I grant M3’s motion for entry of judgment in the amount of amount of $762,747, which is comprised of $254,249 for lost profits from Bard’s predatory conduct trebled as required by § 4 of the Clayton Act. I also grant M3’s motion for postjudgment interest from the time of entry of the first judgment in this case.

I. Background

In August 1993, Bard, the patent holder for “biopsy guns” used to take samples of body tissue for biopsy purposes, sued M3 Systems asserting that M3’s ProMag biopsy gun and ACN/SACN biopsy needle assemblies infringed its patents. In response, M3 raised the defenses that the patents were invalid and not infringed, and also raised counterclaims and sought damages on three theories, namely that Bard: (1) fraudulently obtained and misused certain patents, (2) brought the patent infringement claims in bad faith, and (3) made predatory modifications to its reusable biopsy guns so that M3’s needles could not be used in the Bard gun. M3 presented evidence that it had suffered damages of $1,158,395 on the first and second claims 1 and $254,249 in lost profits from replacement needle sales on the predatory gun modification claim, totaling $1,412,644. The jury found in favor of M3 and against Bard on every question and awarded M3 $1,500,000 in compensatory damages, primarily comprised of litigation costs, which were trebled as required by § 4 of the Clayton Act.

Bard appealed the jury’s verdict, and the Federal Circuit held as a matter of law that M3 had proved neither fraud on the *1147 Patent Office nor that Bard’s infringement claims were brought in bad faith. The jury verdict on these counts was reversed. However, the Federal Circuit affirmed the jury’s decision that Bard made predatory modifications to its biopsy-taking guns to prevent the use of M3’s and other competitors’ needles. M3 had to prove that Bard made a change in its gun for predatory reasons, i.e., for the purpose of injuring competitors in the replacement needle market, not to improve the operation of the gun. The jury specifically found that Bard enjoyed monopoly power in the market for replacement needles and that the change in its patented product was made for the purpose of maintaining this monopoly. The Federal Circuit concluded that the evidence was sufficient in this regard. Because only one of the three counterclaims was upheld, but the jury form contained one single damage award, the Federal Circuit remanded the damages award for “further proceedings to determine the proper amount of damages to be assessed on the antitrust counterclaim.” C.R. Bard, Inc. v. M3 Systems, Inc. 157 F.3d 1340, 1346 (Fed.Cir.1998). “The judgment of antitrust violation on the ground of attempt to monopolize is affirmed, but the antitrust damages award is vacated, for redetermination upon remand.” Id. at 1346.

II. Judgment Calculation

M3 seeks an entry of judgment in the amount of $254,249 (before trebling) for the antitrust count upheld on appeal. This amount is taken directly from the damages model M3 submitted to the jury which calculated its lost profits from the decrease in needle sales from Bard’s predatory modification to its biopsy gun. ' Bard argues that a new trial is required to resolve the issue of damages. Bard’s most basic arguments are that the jury was prejudiced and that because its award was not itemized and exceeded M3’s damage request, damages must be retried. 2

Bard claims first that the jury’s verdict was the result of prejudice. According to Bard’s argument, because the Federal Circuit reversed the jury’s verdicts against it for fraud and inequitable conduct, all evidence introduced in support of those claims was irrelevant and prejudicial. Bard identifies several pieces of evidence presented to the jury unrelated to the antitrust monopolization claim which could have prejudiced the jury. These bald, con-clusory assertions are not persuasive. Bard does not deny the accuracy of this evidence or explain how this evidence prejudiced it or why it was that the jury could not consider the counterclaims separately. 3 Bard offers no specific acts of misconduct or evidentiary errors, nor did it present any to the appeals court.

Bard’s only evidence that the jury was in fact prejudiced is that it awarded M3 $1.5 million rather than the $1,412,644 it specifically requested, or approximately 6% more than what it sought. As an explanation, M3 offers that its damage calculation presented to the jury stopped calculating litigation expenses at August 15, 1995 but the trial did not finish until September 28, 1995; it claims that the jury probably awarded the additional amount to cover attorneys fees which accrued over that time. Perhaps the jury simply “rounded up,” not anticipating that conflicting meanings would be attributed to its decision. I do not open the “black box” of jury deliberation. Whatever the reason, the comparatively small difference between the award and M3’s request is not sufficient to conclude that the jury’s verdict was the result of passion or prejudice. Even if the award were excessive, which I do not think it is, prejudice is not inferred from mere excessiveness. Kaminski v. Chicago Riv *1148 er & Indiana R. Co., 200 F.2d 1, 5 (7th Cir.1952). In the Moquin case upon which Bard attempts to rely, the district court itself concluded that the jury was impacted by prejudice. I make no such finding here. Moreover, Bard’s suggestion that evidence from the two counts rejected by the Federal Circuit is necessarily prejudicial enough to require a new trial would demand a new trial in every case in which an improper conduct claim, but not another claim, fails to withstand appeal. I reject such a suggestion, which underestimates the intellect and integrity of juries and would have far-reaching implications as to the finality of their verdicts.

Bard next argues that the damages from the surviving claim cannot be determined because the overall award was not itemized; to award the damages from the lost profits model would be impermissible guesswork. 4 Bard relies upon the case cited by the Federal Circuit, MCI Communications Corp. v. AT & T, 708 F.2d 1081

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Moran Foods, Inc. v. Mid-Atlantic Market Development Co.
500 F. Supp. 2d 1079 (N.D. Indiana, 2007)
Ugine-Savoie Imphy v. United States
121 F. Supp. 2d 684 (Court of International Trade, 2000)
Kossman v. Northeast Illinois Regional Commuter Railroad
114 F. Supp. 2d 727 (N.D. Illinois, 2000)

Cite This Page — Counsel Stack

Bluebook (online)
120 F. Supp. 2d 1145, 2000 WL 875736, Counsel Stack Legal Research, https://law.counselstack.com/opinion/cr-bard-inc-v-m3-systems-inc-ilnd-2000.